<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598725</url>
  </required_header>
  <id_info>
    <org_study_id>BCH-ITI-20180123</org_study_id>
    <nct_id>NCT03598725</nct_id>
  </id_info>
  <brief_title>Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China</brief_title>
  <acronym>HA-LD-ITI</acronym>
  <official_title>Beijing Children's Hospital, Capital Medical University</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study start on January 18, 2017. The Severe(FⅧ&lt;1%) and moderate hemophilia A
      (FⅧ1%～5%)children with high titer inhibitor(historical peak inhibitor titer≥5BU ) combining
      with poor ITI risk(s) were enrolled. The low-dose ITI was alone or combined with
      immunosuppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Poor risk(s) includes:①peak historical inhibitor titer≥200BU ②inhibitor titer≥10BU before ITI
      initiation ③peak inhibitor titer during ITI≥200BU ④time to titer decline to&lt;10BU before
      ITI≥24 months ⑤age≥8 years at start of ITI ⑥ITI initiated ≥5 years after inhibitor diagnosis
      ⑦interruptions in ITI≥2 weeks in duration. The low-dose ITI strategy consist of
      FⅧ（25-50IU/kg）alone or combining with immunosuppression: prednisone and Rituximab when the
      inhibitor titer ≥40BU ml/ml before or during ITI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate</measure>
    <time_frame>2 years</time_frame>
    <description>Success rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding Rate</measure>
    <time_frame>2 year</time_frame>
    <description>How many times for all types of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Joint Bleeding Rate</measure>
    <time_frame>2 year</time_frame>
    <description>How many times for joint bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success time</measure>
    <time_frame>2 years</time_frame>
    <description>How long to success</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Hemophilia A With Inhibitor</condition>
  <arm_group>
    <arm_group_label>ITI strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coagulation Factor VIII</intervention_name>
    <description>Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day</description>
    <arm_group_label>ITI strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>2mg/kg every day for 4 weeks then typering in 3 months</description>
    <arm_group_label>ITI strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/Square meter for consecutive 4 months</description>
    <arm_group_label>ITI strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males

          -  from 1 to 14 years old

          -  severe or moderate hemophilia A;

          -  inhibitors positive before ITI started.

        Exclusion Criteria:

          -  Females

          -  ＜1 or ＞14 years old

          -  hemophilia B or mild haemophilia A;

          -  inhibitor negative before ITI started.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Ni, master</last_name>
    <phone>010-59616643</phone>
    <email>nixin@bch.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Children's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Runhui Wu, master</last_name>
      <phone>0086-010-59617621</phone>
      <email>runhuiwu@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 23, 2018</last_update_submitted>
  <last_update_submitted_qc>July 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Children's Hospital</investigator_affiliation>
    <investigator_full_name>Runhui WU</investigator_full_name>
    <investigator_title>Capital Medical Univercity</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

